A Single Fasting Plasma 5-HIAA Value Correlates with 24-Hour Urinary 5-HIAA Values and Other Biomarkers in Midgut Neuroendocrine Tumors (NETs) Abstract #595

Introduction: 5-hydoxyindoleacetic acid (5-HIAA) is used for the evaluation of neuroendocrine tumors (NETs), however, the current 5-HIAA assay requires a 24-hour urine collection which is inconvenient.
Aim(s): We developed a gas chromatography-mass spectroscopy (GC-MS) based plasma 5-HIAA assay.
Materials and methods: We compared 24-hour urine 5-HIAA values with single fasting plasma 5-HIAA values in 115 mixed variety NET patients, a subset of 72 patients with only small bowel NETs, and another subset of 47 patients with small bowel NETs with liver metastasis. We also compared the information gained from urinary and plasma 5-HIAA values with other biomarkers of midgut NET activity in order to determine the plasma assay’s clinical implications.
Conference: 10th Annual ENETS Conference 2013 (2013)
Category: Medical treatment - Chemotherapy
Presenting Author: Eugene Woltering

To read results and conclusion, please login ...

Further abstracts you may be interested in

#325 Effect of Everolimus + Octreotide LAR Treatment on 5-Hydroxyindoleacetic Acid Levels in Patients With Advanced Neuroendocrine Tumors: Phase III RADIANT-2 Study Results
Introduction: Urinary 5-hydroxyindoleacetic acid (5-HIAA) is a metabolite and surrogate measure of plasma serotonin, an important cause of carcinoid syndrome in patients with neuroendocrine tumors (NET).
Conference: 8th Annual ENETS Conference (2011)
Category: Clinical
Presenting Author: Eric Baudin
#796 Somatostatin Analogues for Preventing Carcinoid Crisis
Introduction: Carcinoid crisis is a life-threating syndrome of neuroendocrine tumors (NETs) and is characterized by dramatic blood pressure fluctuation, arrhythmias, and bronchospasm. Somatostatin analogues (SSTA) have been recommended for prophylactic administration before provocative procedures.
Conference: 11th Annual ENETS Conference 2014 (2014)
Category: Medical treatment - SMS analogues, interferon
Presenting Author: LinJie Guo
Authors: Guo L, Tang C, ...
#1363 Efficacy of Lutetium-177 DOTA Octreotate Peptide Receptor Radionuclide Therapy in Patients with Advanced Neuroendocrine Tumours and Carcinoid Syndrome Refractory to Somatostatin Analogues
Introduction: Somatostatin Analogues (SSAs) are considered the gold standard treatment in Neuroendocrine Tumours (NETs) and carcinoid syndrome.
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Medical treatment - Targeted therapies
Presenting Author: Dr Apostolos Koffas
#1517 Additional Value for Urinary 5-Hydroxyindoleacetic Acid as Prognostic Marker in Neuroendocrine Tumors?
Introduction: 5-Hydroxyindoleacetic Acid (5-HIAA) is of value for diagnosis of NETs and correlates with severity of carcinoid syndrome. However its value for determining prognosis is uncertain, particularly in combination with other biomarkers
Conference: 13th Annual ENETS conference 2016 (2016)
Category: Epidemiology/Natural history/Prognosis - Prognosis
Presenting Author: Wouter Zandee
Keywords: prognosis 5-HIAA
#2694 The Incidence of Gastrointestinal Neuroendocrine Tumors in the Russian Population
Introduction: Over the past four decades, the incidence of neuroendocrine tumors (NETs) has increased. The limited choice of treatments, broad clinical variability of the syndrome explains the increased interest in NETs.
Conference: 17th Annual ENETS Conference 2020 (2020)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Alina Isiangulova